Clinical Trial

A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC)

Name: A Study of Valemetostat (DS-3201b) in Combination With Darolutamide in Metastatic Castration Resistant Prostate Cancer (mCRPC) — clinical trial record (NCT07244341)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Recruiting Phase 1

View on ClinicalTrials.gov →

Summary

This study will assess the safety and tolerability of valemetostat in combination with darolutamide in participants with Metastatic Castration Resistant Prostate Cancer (mCRPC).

Protocol Amendment History 1 change

notable Trial sites expanded: 6 -> 19 locations 2026-05-16

Trial Details

NCT Number	NCT07244341
Lead Sponsor	Daiichi Sankyo Collaborators: Bayer
Conditions	Metastatic Castration-resistant Prostate Cancer
Enrollment	60 participants
Start Date	2025-12-03
Primary Completion	2028-01-31 (estimated)
Study Completion	2029-11-30 (estimated)
Updated on ClinicalTrials.gov	2026-05-15